250-13951-306 Enrolling

Women’s Androgenetic Alopecia Study (14 Months)


Treatment: Oral Age: 18 Years


Who Can Participate?
Women aged 18 to 65 with mild to moderate androgenetic alopecia may participate.

Inclusion Criteria
• have a clinical diagnosis of mild to moderate AGA
• willing to maintain the same hair care regimen with the same hair care products throughout the study
• willing to maintain at least ¼ inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study

Participant Information
• Participate and receive study treatment at no cost
• Regular visits with study doctors who specialise in treating androgenetic alopecia (11 visits)
• Will receive either an investigative oral treatment (study drug) or an inert tablet
• Reimbursement for study-related expenses may be provided

How Long Will The Study Last?
• 62 weeks

Note: Participants will need to stop all other treatments for androgenetic alopecia during clinical trial participation. Some over-the-counter preparations may be deemed acceptable by the doctor performing the study.


Participating Locations

COUNTRY
country-icon
United States

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: October 31, 2025

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia

ClinicalTrials.gov ID

NCT07146022

Sponsor

Veradermics, Inc.

Study Description

  • Brief Summary:

    This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

  • Condition or Disease:

    Androgenetic Alopecia (AGA),Androgenetic Alopecia,AGA,Female Androgenetic Alopecia,Hair Loss

  • Intervention/Treatment:

    Drug: VDPHL01 BID Drug: VDPHL01 QD,Drug: Placebo Drug: Placebo Drug: Placebo
  • Phase:

    PHASE3

  • Ages Eligible for Study:

    18 Years and 65 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    FEMALE


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Androgenetic Alopecia

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content